Industry Events Calendar

Built with Inflammasome Therapeutics, GSK, and Novartis, the 2nd Inflammasome Therapeutics Summit is the only industry focused meeting dedicated to solving the challenges of targeting the inflammasome to develop clinically effective therapeutics. Bringing together over 200 of the industry’s leading experts to one virtual meeting, this event will gather pharma, biotech and academia to overcome the challenges and opportunities the inflammasome field is facing.

This year’s summit will once again unite thought leaders in inflammasome drug development to discuss clinical developments in 2019/2020, share novel inflammatory pathways outside of NLRP3, the development of the NLRP3 pathway and translate these into clinically effective therapeutics.

Register now

There is an increasing abundance of research focused on modulating the microbiome through nutritional approaches. However, there is still a number of unique challenges that need to be addressed to further product development. This event provides the solutions to the functional, clinical and practical applicability challenges of microbiome-targeted research within the consumer health industry.

Register now

PEGS Europe is the leading European event with comprehensive programming covering all aspects of protein and antibody engineering. Last year, close to 1,300 delegates from 40 countries convened in beautiful Lisbon, Portugal to discuss the latest advances in protein and antibody engineering, with over 75% from pharma and biotech organizations.

Register now

Emi Gonzalez, Principal, Social Starts and Joyance Partners, will moderate this panel that will discuss the current state of metabesity. What is it, and how should the industry respond? What are companies working on in this field?

Sara Demy, CEO of Demy-Colton, hosts interactive virtual salons featuring industry leaders and distinguished guests exploring today’s most consequential and disruptive topics in healthcare.

Register now

Solving the Translational Drug Development Gap, From Fibrotic Mechanisms to Clinically Effective Therapeutics.

Register now

The coronavirus pandemic reset our expectations of what’s possible. New medicines and vaccines are being developed at a previously unimaginable pace. Telemedicine has replaced the doctor’s office. Now, we’re starting to figure out how the world has been reshaped in the wake of Covid-19, pushing us to reexamine long-standing inequities in health care and make new discoveries at top speed.
As we work to navigate this new order, we invite you to join us — and some of the greatest minds in science and medicine — for our virtual 2020 STAT Summit. Interested?

Get your ticket now
Discounted rates are available for STAT Plus subscribers, as well as those in the academic and non-profit spaces. Please email us at summit@statnews.com for more information.

Learn more

The causative agent of COVID-19, SARS-CoV-2 virus, appears to lead to a multi-system disease that affects the human host widely beyond the respiratory tract. Acute cardiovascular complications include myocarditis, myocardial infarction, arrhythmia, and cardiac arrest. Case-mortality rate is up to 5-fold higher for those with pre-existing cardiovascular diseases.

In early reports, detectable cardiac changes are seen in up to 70+% of patients post clinical recovery, including those who have recovered from mild COVID, and young and athletic people with no co-morbidities. This has potentially enormous implications for long-term cardiovascular health globally given the 50 million world-wide reported cases to date. We face significant challenges in the diagnosis, monitoring, and treatment of the potential long-term cardiac complications of COVID-19.

Key Discussion Topics

• Recent studies and current clinical evidence

• What this means for long-term care and monitoring for COVID-19 patients

• Should hospitals conduct follow-up cardiac monitoring and care?

• What are the long-term implications of these recent findings?

Moderated by Sara Jane Demy, CEO & Founder, Demy Colton, this virtual salon features the following panelists:

Bob S. Hu, MD, is Director of Cardiac MRI at Sutter Health. He is Board certified in cardiovascular disease and internal medicine, practices at PAMF’s Palo Alto Center. His interests include anatomic vascular studies, non-invasive cardiac testing, transesophageal echocardiography, cardiac imaging, and cardiovascular magnetic resonance imaging. Dr. Hu completed his medical training and residency at Stanford University. He is involved in the American College of Cardiology and American Heart Association.

Prof. Eike Nagel, MD, PhD, FESC, FACC, FRCR is a Professor and Director of the Institute for Experimental and Translational Cardiovascular Imaging at the University Hospital Frankfurt am Main. From 2007 to 2015 he was Professor and Head of the Department of Clinical Cardiovascular Imaging at King’s College London.

With 300 scientific publications, 30 book chapters and 20,000 citations, Nagel is a pioneer in the research and clinical use of MRI of the heart. In a ground breaking paper published in the New England Journal of Medicine in 2019, Nagel and an international consortium were able to show that patients with stable chest pain (angina pectoris) can be guided as safely with non-invasive perfusion MRI as with the invasive cardiac catheterization currently used as the routine technique, saving many cardiac catheterizations. It was shown that in more than 3/4 of the infected patients the heart is affected and especially also many people with benign courses of the disease (few symptoms, no hospital stay) have mild heart muscle inflammation (myocarditis) or pericarditis. While the long-term effects of these abnormalities are not yet known, there is strong evidence that COVID-19 can cause some damage of the heart.

In 2016 he received the Gold Medal of the Society for Cardiovascular Magnetic Resonance (SCMR) for his merits in the field of science and establishment of MRI for clinical applications.

Eric Topol, MD, is the Founder and Director of the Scripps Research Translational Institute, Professor, Molecular Medicine, and Executive Vice-President of Scripps Research. As a researcher, he has published over 1,200 peer-reviewed articles, with more than 280,000 citations, elected to the National Academy of Medicine, and is one of the top 10 most cited researchers in medicine. His principal scientific focus has been on the genomic and digital tools to individualize medicine.

In 2016, Topol was awarded a $207 million grant from the NIH to lead a significant part of the Precision Medicine (All of Us) Initiative, a prospective research program enrolling 1 million participants in the US. This is in addition to his role as principal investigator for a flagship $35M NIH grant to promote innovation in medicine. He was the founder of a new medical school at Cleveland Clinic, Lerner College of Medicine, with Case Western University. He has over 280,000 followers on Twitter (@EricTopol) where recently he has been reporting insights and research findings for COVID-19. Besides editing several textbooks, he has published 3 bestseller books on the future of medicine: The Creative Destruction of Medicine, The Patient Will See You Now, and Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Lastly, Topol was commissioned by the UK 2018-2019 to lead planning for the National Health Service’s integration of AI and new technologies.

Register now

In this Harvard Medical School webinar, Bill Evans CEO & Managing Director of Rock Healt, will examine emerging business models and the state of digital health in a very dynamic clinical, reimbursement and regulatory environment.

Register now